Top stories of 2009

S K Todi. Indian J Crit Care Med. 2010 Jan.

. 2010 Jan;14(1):3-7.

doi: 10.4103/0972-5229.63027.

S K Todi¹

¹ Director - Critical Care & Emergency Medicine, AMRI Hospitals, Kolkata, India.

No abstract available

Conflict of interest statement

Conflict of Interest: None declared.

1. Hochreiter M, Köhler T, Schweiger AM, Keck FS, Bein B, von Spiegel T, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: A randomized prospective controlled trial. Crit Care. 2009;13:R83. - PMC - PubMed
1. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widemer I, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: The ProHOSP randomized controlled trial. JAMA. 2009;302:1059–66. - PubMed
1. Tsangaris I, Plachouras D, Kavatha D, Gourgoulis GM, Tsantes A, Kopterides P, et al. Diagnostic and prognostic value of procalcitonin among febrile critically ill patients with prolonged ICU stay. BMC Infect Dis. 2009;9:213. - PMC - PubMed
1. Jang TN, Lee SH, Huang CH, Lee CL, Chen WY. Risk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: A case-control study. J Hosp Infect. 2009;73:143–50. - PubMed
1. Jamal W, Salama M, Dehrab N, Al Hashem G, Shahin M, Rotimi VO. Role of tigecycline in the control of a carbapenem-resistant Acinetobacter baumannii outbreak in an intensive care unit. J Hosp Infect. 2009;2:234–42. - PubMed